Showing results (71-80 of 192) with videos related to
Sort By:
Pageof 20
Analytical Chemistry|July 3, 2019
Phenotypic Profiling of Circulating Tumor Cells in Metastatic Prostate Cancer Patients Using Nanoparticle-Mediated RankingBrenda J Green, Vivian Nguyen, Eshetu Atenafu, et al.Journal of Nuclear Medicine : Official Publication, Society of Nuclear Medicine|December 16, 2018
Rapid Modulation of PSMA Expression by Androgen Deprivation: Serial <sup>68</sup>Ga-PSMA-11 PET in Men with Hormone-Sensitive and Castrate-Resistant Prostate Cancer Commencing Androgen BlockadeLouise Emmett, Charlotte Yin, Megan Crumbaker, et al.The Prostate|September 2, 2014
A retrospective, Canadian multi-center study examining the impact of prior response to abiraterone acetate on efficacy of docetaxel in metastatic castration-resistant prostate cancerArun A Azad, Raya Leibowitz-Amit, Bernhard J Eigl, et al.Nature Reviews. Clinical Oncology|January 4, 2023
Advances in the clinical management of uveal melanomaRichard D Carvajal, Joseph J Sacco, Martine J Jager, et al.Journal of Nuclear Medicine : Official Publication, Society of Nuclear Medicine|June 23, 2022
The Prognostic Value of Posttreatment <sup>68</sup>Ga-PSMA-11 PET/CT and <sup>18</sup>F-FDG PET/CT in Metastatic Castration-Resistant Prostate Cancer Treated with <sup>177</sup>Lu-PSMA-617 and NOX66 in a Phase I/II Trial (LuPIN)Sarennya Pathmanandavel, Megan Crumbaker, Andrew Nguyen, et al.European Journal of Cancer (Oxford, England : 1990)|July 22, 2014
Abiraterone acetate in metastatic castration-resistant prostate cancer: a retrospective review of the Princess Margaret experience of (I) low dose abiraterone and (II) prior ketoconazoleRaya Leibowitz-Amit, Jo-An Seah, Eshetu G Atenafu, et al.BMJ Open|January 29, 2020
Pharmacodynamics effects of CDK4/6 inhibitor LEE011 (ribociclib) in high-risk, localised prostate cancer: a study protocol for a randomised controlled phase II trial (LEEP study: LEE011 in high-risk, localised Prostate cancer)Tahlia Scheinberg, James Kench, Martin Stockler, et al.Clinical Genitourinary Cancer|November 15, 2018
Results of a Prospective Phase 2 Pilot Trial of <sup>177</sup>Lu-PSMA-617 Therapy for Metastatic Castration-Resistant Prostate Cancer Including Imaging Predictors of Treatment Response and Patterns of ProgressionLouise Emmett, Megan Crumbaker, Bao Ho, et al.BMC Cancer|October 7, 2006
Effects of THBS3, SPARC and SPP1 expression on biological behavior and survival in patients with osteosarcomaCristiane A Dalla-Torre, Maisa Yoshimoto, Chung-Hae Lee, et al.Journal of Nuclear Medicine : Official Publication, Society of Nuclear Medicine|July 28, 2017
Treatment Outcomes from <sup>68</sup>Ga-PSMA PET/CT-Informed Salvage Radiation Treatment in Men with Rising PSA After Radical Prostatectomy: Prognostic Value of a Negative PSMA PETLouise Emmett, Pim J van Leeuwen, Rohan Nandurkar, et al.Pageof 20